

Thermodynamic Considerations on the Biophysical Interaction between Low-Energy Electromagnetic Fields and Biosystems

Original

Thermodynamic Considerations on the Biophysical Interaction between Low-Energy Electromagnetic Fields and Biosystems / Lucia, U., Grisolia, G.. - In: MEMBRANES. - ISSN 2077-0375. - ELETTRONICO. - 14:8(2024), pp. 1-12. [10.3390/membranes14080179]

Availability:

This version is available at: 11583/2991883 since: 2024-08-23T08:17:55Z

Publisher:

MDPI

Published

DOI:10.3390/membranes14080179

Terms of use:

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)

Article

Thermodynamic Considerations on the Biophysical Interaction between Low-Energy Electromagnetic Fields and Biosystems

Umberto Lucia ^{1,*}  and Giulia Grisolia ^{2,*} 

¹ Dipartimento Energia “Galileo Ferraris”, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Torino, Italy

² Dipartimento di Ingegneria dell’Ambiente, del Territorio e delle Infrastrutture, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Torino, Italy

* Correspondence: umberto.lucia@polito.it (U.L.); giulia.grisolia@polito.it (G.G.); Tel.: +39-011-090-4558 (U.L.)

† And also INFN-Sezione di Torino.

Abstract: A general theory explaining how electromagnetic waves affect cells and biological systems has not been completely accepted yet; nevertheless, extremely low-frequency electromagnetic fields (ELF-EMFs) can interfere with and modify several molecular cellular processes. The therapeutic effect of EMFs has been investigated in several clinical conditions with promising results: in this context a better understanding of mechanisms by which ELF-EMF influences cellular events is necessary and it could lead to more extended and specific clinical applications in different pathological conditions. This paper develops a thermodynamic model to explain how ELF-EMF directly interferes with the cellular membrane, inducing a biological response related to a cellular energy conversion and modification of flows across cell membranes. Indeed, energy, irreversibly consumed by cellular metabolism, is converted into entropy variation. The proposed thermodynamic model views living systems as adaptive open systems, analysing the changes in energy and matter moving in and out of the cell.

Keywords: extremely low-frequency electromagnetic fields (ELF-EMFs); living systems; membrane ions fluxes; bioengineering thermodynamics; biochemical thermodynamics



Citation: Lucia, U.; Grisolia, G.

Thermodynamic Considerations on the Biophysical Interaction between Low-Energy Electromagnetic Fields and Biosystems. *Membranes* **2024**, *14*, 179. <https://doi.org/10.3390/membranes14080179>

Academic Editors: Zhongcan Ouyang and Hao Wu

Received: 16 June 2024

Revised: 23 July 2024

Accepted: 21 August 2024

Published: 22 August 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Extremely low-frequency electromagnetic fields (ELF-EMFs) are defined by the International Telecommunication Union as electromagnetic radiation (radio waves) with frequencies from 3 to 30 Hz. In atmospheric sciences, an alternative definition is usually given, from 3 Hz to 3 kHz. Moreover, United States Government agencies, such as NASA, describe ELF as non-ionising radiation with frequencies between 0 and 3 kHz [1]. The World Health Organization (WHO) have used ELF-EMF to refer to the concept of “extremely low frequency (ELF) electric and magnetic fields (EMF)” [2]. The WHO also stated that at frequencies between 0 and 3 kHz, “the wavelengths in air are very long (6000 km at 50 Hz and 5000 km at 60 Hz), and, in practical situations, the electric and magnetic fields act independently of one another and are measured separately” [2]. In the ELF range (<3 kHz), the electric and magnetic fields can be considered de-coupled: the electric component may barely diffuse in the human body, while the magnetic component may well penetrate the body nearly un-attenuated [3].

ELF-EMFs have been crucial for the development of life on the Earth, contributing to cell division, governing many other bio-processes [4–6], e.g., gene expression, protein transcription, and phosphorylation, and influencing cell functions such as proliferation, differentiation, and apoptosis. Many bio-molecular mechanisms were suggested to explain how ELF-EMFs may affect cells and biological systems [4]; nevertheless, numerous biochemical effects were described related to the biological model considered, intrinsic

susceptibility/responsiveness of different cell types, duration of the exposure and the selected electromagnetic frequency [7]. Among the described effects, ELF-EMFs have already been well established to affect ion fluxes across the plasma membrane, regulating a lot of membrane-mediated signal transduction processes, especially concerning Na^+ , K^+ , Cl^- , Ca^{2+} , Fe^{2+} , Mn^{2+} , and Mg^{2+} fluxes [8].

This evidence is of particular interest concerning biochemical and biophysical processes because Na^+ , K^+ , and Cl^- ion fluxes regulate membrane electric potential, while Ca^{2+} and Mg^{2+} ion fluxes control protein folding, Zn^{2+} controls HCO_3^- formation, and Fe^{2+} activates molecular oxygen and works as a catalyst for the generation of reactive oxygen species (ROS) in pathological conditions such as carcinogenesis, inflammation, and perfusion injury. Consequently, the results of ELF use for ion flux control are interesting for possible future therapies in different diseases. Indeed, in human cells and tissues, ELF-EMF effects were tested by using some frequency ranges to evaluate potential clinical applications [9] aiming to ameliorate different pathological conditions.

Moreover, the electrochemical communication between cells is recognised as an essential requirement, and the ELF-EMF can interfere with this communication by interacting with the cell membrane and affecting the mobility of ions. These ions include some metal cations such as Zn^{2+} , Fe^{2+} , Cu^+ , Mg^{2+} , and Ca^{2+} , which play a crucial role in cell signalling. Specifically, calcium influx through cell membranes has received attention concerning cell communication and EMF interaction, due to the huge variety of intracellular mechanisms that depend on it. The applied EMF, especially one with low energy, can modify existing signal transduction processes in cell membranes because EMF frequencies in the body are normally extremely low and include, for example, the action potentials of nerves, myocardocytes, and skeletal muscle tissues [10,11]. For example, a resonant frequency [12–14] of calcium-gated channels was applied to cells, causing physiological depolarisation and natural activation of the cells [15–17].

Several studies investigated the increase in intracellular Ca^{2+} and the higher activity of voltage-gated calcium channels (VGCCs) after exposure to EMF. These changes were investigated and demonstrated in many cell types by using calcium channel blockers to lower or block the cell signalling changes induced by EMF [18–20]. Changes in calcium signalling in response to ELF-EMF exposure were highlighted in mitogen-activated rat thymocytes and the activity of immune cells [21,22]; on rat pituitary cells, a 50 Hz magnetic field was shown to increase intracellular Ca^{2+} concentration [23]. A calcium-dependent mechanism is proposed to explain the observed changes in cell shape, preferential orientation, and migration, after field exposure of mouse embryo fibroblasts [24], and the calcium increase was inhibited by Ca^{2+} channel blocker D-600. Calcium concentration can also be altered in histamine-activated HL-60 human leukaemia cells, after 60 Hz EMF exposure, resulting in a 20–40% increase in intracellular Ca^{2+} . The observed effects were reversible, which could mean the absence of permanent structural damages induced by acute 60 min exposure to this EMF on ion channels [25].

A possible connection between ELF-EMF and voltage-gated calcium channels (VGCCs) in cell proliferation and apoptosis has been more recently studied [15] in human neural and rat neuroendocrine cells, showing significantly enhanced proliferation, around 40%, and a related limitation of apoptosis after H_2O_2 treatment in both cell types after exposure. In this paper, they provided direct evidence of EMF enhancing the expression of VGCCs on the plasma membrane of the exposed cells increasing the number of VGCCs, not only the calcium current density.

A decrease in Cl^- intracellular concentration is directly linked to the malignant proliferation of cancer [26], while an increase in Na^+ intracellular concentration generates depolarisation of the cell membrane, with a related consequence on the mitotic activity [26–44]. On the contrary, hyper-polarisation causes an activation of the Ca^{2+} - K^+ channel, which increases the intracellular Ca^{2+} concentration [26,45,46], pointing out the Ca^{2+} - K^+ channel's role in the control of the membrane electric potential [26,47]. Last, an increase in Na^+ concentration inside the cell causes inflammation [48].

The effects of extremely low-frequency electromagnetic fields on biological systems have been the subject of debate for over fifty years [49]. Experimental studies have often obtained contradictory results, making it challenging to draw clear conclusions. As a result, our understanding of the interaction between ELF-EMF and biological systems is still not fully developed, despite its fundamental importance for future applications [3,49].

This paper proposes a thermodynamic approach to ion fluxes to model the effect of ELF-EMFs on cell behaviour, with a particular focus on controlling inflammation related to ion fluxes. The Section 2 introduces the thermodynamic model, developing the biophysical basis of interaction between ELF-EMFs and cells, and highlighting the thermodynamic approach to the mechano-biological behaviour of cells. In the Section 3, we delve into the concept of thermal resonance, exploring the heat exchange between the cell and its environment. Through this biophysical approach, we present a summary of experimental results that serve to validate the introduced thermodynamic model. In the Section 4, we will delve into the evolution of knowledge and the approaches introduced in the last century, emphasising how our approach effectively addresses the demands for experimental repeatability, as well as thermodynamic and biophysical considerations. In the Section 5, we provide some insights into the potential use of ELF-EMFs as a therapeutic approach to complement existing therapies.

2. Materials and Methods

To explain the existing confined interactions between EMFs and cell systems, we considered the effects of ELF-EMFs from a thermodynamic perspective; indeed, cells obey thermodynamic laws by transforming and dissipating energy [50] into work and disorder, respectively.

Here, we highlighted cells that respond to ELF interaction by shifting their energy conversion, and their metabolic change increases the entropy generation by changing the cell's specific functions. Consequently, the partial dissipation of the assimilated energy from metabolites is converted into entropy variation, allowing us to study cells as adaptive thermodynamic engines that convert energy by coupling metabolic and biochemical reactions with transport processes [51], sustained by the mass, energy, and ion fluxes through the cell membrane.

From a thermodynamic viewpoint, a cell can be considered a macroscopic system because of the large number of molecules it contains, as well as the energy concentration and cell temperature. Ion concentration follows the relation [52,53]

$$c_{in} = c_{out} \exp\left(-\frac{ZF\Delta\phi}{RT}\right) \quad (1)$$

where c is the molecule number concentration, in and out subscripts mean inside and outside of the membrane, respectively, T represents the temperature, $R = 8.314 \text{ J K}^{-1} \text{ mol}^{-1}$ is the ideal gas constant, and $\Delta\phi$ represents the membrane electric potential expressed by the Goldman–Hodgkin–Katz equation [52,53]:

$$\Delta\phi = \frac{RT}{ZF} \log_{10} \left(\frac{P_{\text{Na}^+} [\text{Na}^+]_{out} + P_{\text{K}^+} [\text{K}^+]_{out} + P_{\text{Cl}^-} [\text{Cl}^-]_{out}}{P_{\text{Na}^+} [\text{Na}^+]_{in} + P_{\text{K}^+} [\text{K}^+]_{in} + P_{\text{Cl}^-} [\text{Cl}^-]_{in}} \right) \quad (2)$$

where Z is the ion's valence, P is its permeability, $[A]$ means A-ion concentration, and F is the Faraday constant. This last relation highlights that the cell membrane potential can be modified by alterations in the one or more ion fluxes. The ion channels and transporters provide different permeability to distinct ions, such as Na^+ , K^+ , Ca^{2+} and Cl^- . Typical concentrations of the principal ions are [52]

- Na^+ : 150.0 mM extracellular, 15.0 mM intracellular;
- K^+ : 4.5 mM extracellular, 120.0 mM intracellular;
- Cl^- : 116.0 mM extracellular, 20.0 mM intracellular;

- Ca^{2+} : 1.2 mM extracellular, 10^{-4} mM intracellular.

Now, considering Equation (1), we can obtain the value of the cell membrane electric potential for the same ions:

- Na^+ : $\Delta\phi = 59$ mV;
- K^+ : $\Delta\phi = -85$ mV;
- Cl^- : $\Delta\phi = -45$ mV;
- Ca^{2+} : $\Delta\phi = 121$ mV.

However, the membrane electric potential can also be evaluated by considering the Nernst equation [52]:

$$ZF \Delta\phi = \Delta G + 2.3 RT \Delta\text{pH} \Rightarrow ZF d\phi = dG + 2.3 RT d\text{pH} \quad (3)$$

where G is the Gibbs potential, $F = 96,485.34 \text{ A s}^{-1} \text{ mol}^{-1}$ is the Faraday constant, $2.3 \Delta\text{pH}$ is the physiological concentration gradient, and H^+ is the hydrogen ion which is used by the cells in order to modulate the membrane electric potential by changing the H^+ concentration. At human standard temperature (37°C), $k_B T/e = RT/F \approx 26.7$ mV.

Concerning the electromagnetic waves, we consider that they generate a radiation pressure [54]:

$$p = \frac{\epsilon E^2}{2} = \frac{B^2}{2\mu} \Rightarrow dp = \epsilon E dE = \frac{B}{\mu} dB \quad (4)$$

where E and B are the amplitudes of the electric field and magnetic field components, respectively, μ is the magnetic permeability, and $c = 1/\sqrt{\mu_0\epsilon_0} \approx 3 \times 10^8 \text{ m s}^{-1}$ is the velocity of light, with $\epsilon_0 = 8.854 \times 10^{-12} \text{ A s N}^{-1}\text{m}^{-1}$ being the electric permittivity and $\mu_0 = 4\pi \times 10^{-7} \text{ H m}^{-1}$ the magnetic permeability in vacuum, respectively. As a consequence of this pressure, the membrane is subjected to an elastic force [55]:

$$F = \frac{\epsilon E^2}{2} A 2\pi r \quad (5)$$

where A is the surface of the membrane which the electromagnetic wave hits, while r represents the mean value of the internal cell radius. As a consequence of the membrane surface deformation caused by this force, the membrane's electric potential is affected by local variation:

$$\Delta\phi = E A = \sqrt{\frac{F_{el} A}{\pi \epsilon r}} \Rightarrow d\phi = A dE \quad (6)$$

with the consequence to force the opening of ion channels for inflows and outflows. As such, since in our quest to reduce inflammation, we need to force Na^+ outflow only, we must find the value of E and B . We remember that a pressure variation generates a change in the Gibbs free energy [52]:

$$dG = V dp - S dT + \sum_i \mu_i dN_i = V \epsilon E dE - S dT + \sum_i \mu_i dN_i \quad (7)$$

where V is the volume of the system considered, S is the entropy, μ_i represents the chemical potential of the i -th chemical species, and N stands for the number of particles which flow across the boundary of the system. Experimental results obtained in the last decade have always confirmed this approach [56].

Consequently, an incoming electromagnetic wave can alter the cell membrane potential ϕ , with a consequent change in the ion concentration on both sides of the membrane (Equation (1)).

3. Results

In this paper, we have established a connection between the energy characteristics of electromagnetic waves and the local pressure variation (radiation pressure) as well as the

Gibbs free energy. Consequently, the biological effect of low-frequency electromagnetic waves can be explained by the membrane's elastic response to radiation pressure, by changing the membrane electric potential, and consequently, inducing a change in ion concentration with related flows.

Indeed, considering that a human is an assortment of more than 200 different cell types for a total amount of $(3.7 \pm 0.8) \times 10^{13}$ cells which perform a staggering variety of functions and have a diameter in the range of 10–100 μm , an applied 100 μT magnetic field component of an electromagnetic wave determines an effective value of an applied magnetic field of 70 μT , and a pressure in the order of 0.31–3.13 Pa, with a membrane electric potential variation of 0.04–4.17 mV.

This result must be compared with the normal membrane electric potential of -70 mV and that of cancer cells of around -10 mV. The results are in the order of 0.06–6.00% for normal cells and 0.04–7.00% for cancer cells.

Considering the definition of Gibbs free energy in Equation (3), it follows that

$$\dot{Q} \tau = \Delta H - ZF \Delta \phi - 2.3R T \Delta \text{pH} \quad (8)$$

where H is the enthalpy, and $\dot{Q} = T \dot{S}$, where \dot{S} is the entropy production rate in the environment and the heat results $Q = \dot{Q} \cdot \tau$, with τ characteristic time of the cell system in relation to heat transfer. Equation (8) highlights the mechanism of ELF-EMF by linking the quantity $\Delta \phi + 2.3R T \Delta \text{pH} / F$ to the characteristic time, τ , at a definite value of inflow energy, ΔH , and outflow heat power, \dot{Q} .

To evaluate the characteristic time, τ , the membrane heat transfer, can be considered by introducing the thermokinetic lumped model [57]. Indeed, the cell exchanges heat power with its environment, and this heat outflow is strictly related to the cell's metabolism. The heat outflow can occur by convection with the fluids around the cell [58]:

$$\dot{Q} = \rho_{cell} V c_{cell} \frac{dT_{cell}}{dt} = \alpha A (T_{cell} - T) \quad (9)$$

where ρ_{cell} and V are the cell's mass density and volume, respectively, c_{cell} is the cell's specific heat, T_{cell} is its temperature, α is the coefficient of convection, A is the cell's surface area, which can change during the different cell development phases, and $T_{cell} - T$ is the temperature difference between the cell and its environment temperature. Consequently, the characteristic time τ results in [50]

$$\tau = \frac{\rho_{cell} c_{cell} V}{\alpha A} \quad (10)$$

resulting in a resonant process.

Consequently, at a resonant state, the heat outflow results in its maximum fluxes [59], as a consequence of the definition of resonance. Thus, the increase in heat outflow depolarises the cell membrane and restores normal conditions when the cell system is in an inflammation, cancer, or disease state.

The confirmation of the theoretical results of Equation (10) has been obtained by means of experimental evidence. This investigation involved the growth comparison of specific cancer cell lines when subjected to extremely low-frequency electromagnetic fields (ELF-EMFs) at their resonant frequencies, with the growth of untreated cells from the same lines. For each cell line, the resonant frequency was determined through the analysis of the average geometric parameters of the cells themselves, in accordance with theoretical findings. The ELF-EMF exposure system was constituted by two couples of coaxial coils, wound into a cylindrical frame (external radius: 0.08 m, distance among the couples of coaxial coils: 0.08 m). The external casing of the exposure system was constituted by a box-shaped magnetic metal shield to avoid any interference from the background magnetic field, in order to obtain the cells' exposure just at their resonant frequencies, without external alterations of the signal. When treated, the exposed cells were inserted at the

centre of the box-shaped structure within the incubator, while the control group of the same cell line (untreated cells) were inserted within the same incubator, without any shielding and exposure system. The results summarised in Table 1 show the calculated resonant frequency for each cancer cell line. The cells were exposed to their respective characteristic resonant frequencies, and the impact on their growth was compared to that of the untreated cells. It is worth noting the following:

- The experimental results obtained were repeatable, and the cell's behaviour was consistent;
- The cancer growth rate is reduced by electromagnetic waves at the cell's thermal resonant frequency;
- The phenomenon is selective with respect to the frequencies used, as it must be for a resonant process.

In Table 1, it is evident that the reduction in cancer growth depends on the frequency, which is influenced by the shapes of the cell lines. This suggests that the shape is related to the cell cycle phase. To explore potential applications in therapies, enhancing the ELF-EM effect could involve assessing the average volume/area ratio at different stages of the cell phase. These experimental results have been confirmed in other experiments, which were always conducted on cancer cells (spheroids included) [14,56,60–62].

Table 1. Experimental results obtained concerning the growth variation of some cancer cell lines after exposure to the calculated resonant frequencies under a sinusoidal magnetic field of 100 μ T maximum amplitude [56,62].

Cell Line	Human Cancer	Frequency [Hz]	Growth Change [%]
A375P	melanoma cell line	31	−15
HT-29	colorectal adenocarcinoma	24	−19
GTL16	gastric cancer	14	−24
MCF7	breast cancer	5	−22
SKBR3	breast cancer	8	−18
MDA-MB-231	breast cancer	6	−18

4. Discussion

The interest in using electromagnetic fields for therapy dates back to the 19th century. Nikola Tesla was one of the first to suggest the potential therapeutic use of EMF in 1898 [63]. He observed that high-frequency currents seemed to pass through the body without causing pain or discomfort, indicating that tissues act as capacitors [63]. In 1932, Dr. Gustave Kolischer reported at a seminar by the American Congress of Physical Therapy in New York that Tesla's high-frequency electrical currents were producing highly beneficial results in treating cancer, surpassing the outcomes achievable with regular surgery [64].

In 1922, the pioneering work of Russian histologist Alexander Gurvich and his wife revealed a groundbreaking discovery. They found that living cells, when separated by quartz glass, could communicate vital cell information. Through numerous experiments, they suggested that this information was transmitted by invisible light waves in a UV frequency spectrum that passed through quartz and was stopped by window glass [65]. This remarkable work provided the first documented evidence of biophotons, which are coherent light emitted by a biosystem. It laid the foundation for the development of later bioelectromagnetic therapy devices. Notably, it was not until the early 1960s that Leningrad State University successfully captured the mitogenic rays using sensitive photomultipliers [64,66].

In 1925, Georges Lakhovsky revolutionised the field by introducing the concept of resonance in ELF-EMF therapeutic effects [67]. He developed the Lakhovsky's Radio-Cellulo-Oscillator, also known as the Multiple-Wave-Oscillator, which emitted low-frequency electromagnetic waves documented to deliver highly effective therapeutic results [64].

Abraham Liboff, a pioneering physicist, uncovered the electric field and geomagnetic ion cyclotron resonance, offering a more accurate explanation for the resonant interaction

of static magnetic fields with endogenous AC electric fields in biological systems [8,68]. Recently, the crucial role of thermodynamics has been underscored in biomedicine by explaining how thermodynamic principles can shed light on the reasons for specific changes in cell and tissue structures that aid in the detection, identification, and staging of cancer [69]. It highlights the fundamental role of entropy in elucidating the different processes taking place in cancerous tissues at various scales and stages. Tissues can be likened to self-assembled and self-organised structures that arise under non-equilibrium conditions, resulting in entropy production and energy dissipation [50,70]. Moreover, their response to external stimuli is contingent on the intrinsic properties of these structures [12,69,71,72].

The approach developed here needs to be considered in this context. It is a thermodynamic approach that deals with open systems under non-equilibrium conditions, just like real cells. This approach is based on the fundamental conservation laws of thermodynamics: the conservation of mass, charge, and energy. Additionally, it takes into account the fundamental parameter of the cell's membrane, which is the electric potential, as pointed out by Cone Jr. in 1969 [73–75]. Furthermore, this approach is built upon the thermal resonance effect and assesses irreversibility through the measurement of entropy.

Finally, this approach is easy to assess, based on fundamental laws of nature, and it has consistently yielded reproducible experimental results over the past decade.

5. Conclusions

ELF-EMFs are being successfully used in modern medicine to address certain health issues, especially those for which conventional medicine has not yet produced satisfactory results. This therapy offers a non-invasive future approach to treating the injury site, pain, and inflammation in different pathologies [76]. In this paper, we reported some of the possible therapeutic applications of ELF-EMFs in the treatment of various clinical conditions, focusing on biological endpoints such as pain relief, improved healing in skeletal trauma and cutaneous wounds, and containment of malignant tumour progression. The identification and exposition of tumour-specific ELF-EMFs have been suggested for containing cancer without any side effects or toxicity [77,78] even in patients with advanced cancer or inflammation. Existing data show that ELF-EMF exposure could extend patients' survival time, limit cancer cell replication, stimulate apoptosis-like behaviour [79–82], and also impair angiogenesis in solid tumours [83–85].

The effects of ELF-EMF were analysed in association with standard therapies, assuming a possible synergistic effect [79,86,87]. Additionally, it was observed that they could revert the resistance to chemotherapy of cancer cells *in vitro* [88,89]. Other EMF treatments were aimed to improve chemotherapy side effects [90], as well as enhance the well-being of terminally ill patients [91].

There is evidence that EMFs effectively reduce cellular inflammation and pain; indeed, ELF-EMFs have been shown to impact pain and inflammation by modulating G-protein coupling receptors (GPCRs), lowering cyclooxygenase-2 (Cox-2) and nuclear factor kappa B (NF- κ B) necessary to induce inflammatory mediators [92]. ELF-EMFs have the ability to shift the transition from a pro-inflammatory to an anti-inflammatory state, upregulate nitric oxide synthase (NOS) activity, and downregulate Cox-2 expression and Prostaglandin E2 (PGE-2) production, which are involved in the modulation of inflammatory reactions [9,93].

Bone repair stimulation is one of the stronger and better-documented therapeutic effects of EMFs. It is widely used to aid in the healing of fractures by enhancing the proliferation and differentiation of osteoblasts [94,95]; indeed magneto-therapy devices have been successfully used as adjunctive therapy for the treatment of delayed and non-union fractures, fresh fractures, and chronic wounds [96].

In cases of traumatic spinal cord injury where the disruption of axonal transmission of signals leads to neuro-inflammation, neurodegeneration, and cytotoxicity, an alternative method to electrically activate spinal circuits is the application of an external ELF-EMF [97]. In skin and soft tissue healing, ELF-EMF exposure is effective in vascularisation, reduction of wound depth by granulation tissue, and reduced inflammatory cell migration and

infiltration. In a cutaneous wound model *in vitro*, ELF-EMFs were able to enhance migration and proliferation of keratinocytes from the periphery of the wound, switching from the inflammatory phase to the final repair phase and inducing more rapid healing of the wound [98].

In conclusion, although different types of ELF-EMFs are now effectively used in medicine (some examples of possible uses of ELF-EMFs in medicine are summarised from the literature in Table 2), there is still a lack of understanding regarding the basic interaction mechanism between ELF-EMFs and cells. Here, we provide a thermodynamic approach to explain the effects of ELF-EMFs on energy, mass, and ionic flows through the cell membranes and the resultant changes in cell behaviour.

Table 2. Some examples of evidence of possible uses of ELF-EMFs in medicine from the literature [4].

Disease	Frequency [Hz]	Key Finding	Ref.
Arthritis	60	Reduction in pain and inflammation	[99]
Back pain	64	Statistically significant for reducing pain	[100]
Cancer * ¹	0.1–(114 × 10 ³)	Significant decrease in size of tumour * ²	[81]
Carpal tunnel	20	Statistically significant pain reduction * ³	[101]

*¹ breast, colon, and prostate tumours; *² with tumour-specific frequencies; *³ short- and long-term.

The lipid bilayer membrane of a living cell has different specific ion concentrations on each side, regulated by the electro-diffusion caused by the electrochemical gradient of the negative membrane potential (around −70 mV). The cell's functions are controlled by membrane proteins which undergo conformational modifications due to voltage-responsive transduction mechanisms. So, ELF-EMFs' interactions with the membrane are interesting for possible future therapeutic support to some diseases, e.g., cancer and inflammation. Furthermore, electromagnetic waves' interactions with cells are shown to be frequency-dependent due to their resonant nature.

Author Contributions: Conceptualisation, U.L. and G.G.; methodology, U.L.; software, G.G.; validation, U.L.; formal analysis, U.L.; investigation, U.L. and G.G.; resources, U.L.; data curation, G.G.; writing—original draft preparation, U.L. and G.G.; writing—review and editing, U.L. and G.G.; visualisation, U.L. and G.G.; supervision, U.L.; project administration, U.L.; funding acquisition, U.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: All the references for the data are quoted in the paper.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- Center, N.G.R. Non-Ionizing Radiation Safety (Occupational Health Programs Manual—Chapter 10). Document No.: GLM-QS-1800.1.10, NASA, Cleveland. 2017. Available online: <https://www1.grc.nasa.gov/wp-content/uploads/ohpm10.pdf> (accessed on 19 July 2024).
- WHO. Exposure to Extremely Low Frequency Fields. Backgrounder, World Health Organisation, Cleveland. 2017. Available online: <https://www.who.int/teams/environment-climate-change-and-health/radiation-and-health/non-ionizing/exposure-to-extremely-low-frequency-field> (accessed on 19 July 2024).
- Sadafi, H.A.; Mehboodi, Z.; Sardari, D. A Review of the Mechanisms of Interaction Between the Extremely Low Frequency Electromagnetic Fields and Human Biology. In Proceedings of the Progress in Electromagnetics Research Symposium 2006, Tokyo, Japan, 26–29 March 2006.
- Ross, C.L.; Harrison, B.S. The Use of Magnetic Field for the Reduction of Inflammation: A Review of the History and therapeutic Results. *Altern. Ther.* **2013**, *19*, 47–54.
- Pasek, J.; Pasek, T.; Sieroń-Stożny, K.; Cieślak, G.; Sieroń, A. Electromagnetic fields in medicine—The state of art. *Electromagn. Biol. Med.* **2016**, *35*, 170–175. [[CrossRef](#)] [[PubMed](#)]
- Lucia, U.; Grisolia, G. How Life Works—A Continuous Seebeck-Peltier Transition in Cell Membrane? *Entropy* **2020**, *22*, 960. [[CrossRef](#)] [[PubMed](#)]
- Zwolińska, J.; Kasprzak, M.; Kielar, A.; Prokop, M. Positive and Negative Effects of Administering a Magnetic Field to Patients with Rheumatoid Arthritis (RA). *J. Clin. Med.* **2024**, *13*, 1619. [[CrossRef](#)]

8. Liboff, A.R. Geomagnetic Cyclotron Resonance in Living Cells. *J. Biol. Phys.* **1985**, *13*, 99–102. [[CrossRef](#)]
9. D'Angelo, C.; Costantini, E.; Kamal, M.A.; Reale, M. Experimental model for ELF-EMF exposure: Concern for human health. *Saudi J. Biol. Sci.* **2015**, *22*, 75–84. [[CrossRef](#)]
10. Funk, R.H.; Monsees, T.; Ozkucur, H. Electromagnetic effects—From cell biology to medicine. *Prog. Histochem. Cytochem.* **2009**, *43*, 177–264. [[CrossRef](#)] [[PubMed](#)]
11. Kovacic, P.; Somanathan, R. Electromagnetic fields: Mechanism, cell signaling, other bioprocesses, toxicity, radicals, antioxidants and beneficial effects. *J. Recept. Signal Transduct.* **2010**, *30*, 214–226. [[CrossRef](#)]
12. Lucia, U.; Grisolia, G. Thermal resonance in living cells to control their heat exchange: Possible applications in cancer treatment. *Int. Commun. Heat Mass Transf.* **2022**, *131*, 105842. [[CrossRef](#)]
13. Lucia, U.; Grisolia, G. Thermal Resonance and Cell Behavior. *Entropy* **2020**, *22*, 774. [[CrossRef](#)]
14. Lucia, U.; Grisolia, G.; Ponzetto, A.; Bergandi, L.; Silvagno, F. Thermomagnetic resonance affects cancer growth and motility. *R. Soc. Open Sci.* **2020**, *7*, 200299. [[CrossRef](#)] [[PubMed](#)]
15. Grassi, C.; D'Ascenzo, M.; Torsello, A.; Martinotti, G.; Wolf, F.; Cittadini, A.; Azzena, G.B. Effects of 50 Hz electromagnetic fields on voltage-gated Ca²⁺ channels and their role in modulation of neuroendocrine cell proliferation and death. *Cell Calcium* **2004**, *35*, 307–315. [[CrossRef](#)] [[PubMed](#)]
16. Pall, M.L. Electromagnetic fields act via activation of voltage-gated calcium channels to produce beneficial or adverse effects. *J. Cell. Mol. Med.* **2013**, *17*, 958–965. [[CrossRef](#)]
17. Rouleau, N.; Dotta, B.T. Electromagnetic fields as structure-function zeitgebers in biological systems: Environmental orchestrations of morphogenesis and consciousness. *Front. Integr. Neurosci.* **2014**, *8*, 84. [[CrossRef](#)] [[PubMed](#)]
18. Cadossi, R.; Emilia, G.; Ceccherelli, G.; Torelli, G. Lymphocytes and pulsing magnetic fields. In *Modern Bioelectricity*; Marino, A.A., Ed.; CRC Press: Boca-Raton, FL, USA, 1988; pp. 451–496.
19. Papatheofanis, F.J. Use of calcium channel antagonists as magnetoprotective agents. *Radiat. Res.* **1990**, *122*, 24–28. [[CrossRef](#)]
20. Walleczek, J. Electromagnetic field effects on cells of the immune system: The role of calcium signaling. *FASEB J.* **1992**, *6*, 3177–3185. [[CrossRef](#)]
21. Walleczek, J.; Liburdy, R.P. Nonthermal 60 Hz sinusoidal magnetic-field exposure enhances ⁴⁵Ca²⁺ uptake in rat thymocytes: Dependence on mitogen activation. *FEBS Lett.* **1990**, *271*, 157–160. [[CrossRef](#)]
22. Liburdy, R.P. Calcium signaling in lymphocytes and ELF fields. Evidence for an electric field metric and a site of interaction involving the calcium ion channel. *FEBS Lett.* **1992**, *301*, 53–59. [[CrossRef](#)] [[PubMed](#)]
23. Barbier, E.; Dufy, B.; Veyret, B. Stimulation of Ca²⁺ influx in rat pituitary cells under exposure to a 50 Hz magnetic field. *Bioelectromagnetics* **1996**, *17*, 303–311. [[CrossRef](#)]
24. Onuma, E.K.; Hui, S.W. Electric field-directed cell shape changes, displacement, and cytoskeletal reorganization are calcium dependent. *J. Cell Biol.* **1988**, *106*, 2067–2075. [[CrossRef](#)]
25. Kim, Y.V.; Conover, D.L.; Lotz, W.G.; Cleary, S.F. Electric field-induced changes in agonist-stimulated calcium fluxes of human HL-60 leukemia cells. *Bioelectromagnetics* **1998**, *19*, 366–376. [[CrossRef](#)]
26. Binggelli, R.; Cameron, I.L. Cellular Potential of Normal and Cancerous Fibroblasts and Hepatocytes. *Cancer Res.* **1980**, *40*, 1830–1835.
27. Bonora, M.; Bononi, A.; Marchi, E.D.; Giorgi, C.; Lebiedzinska, M.; Marchi, S.; Patergnani, S.; Rimessi, A.; Suski, J.M.; Wojtala, A.; et al. Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. *Cell Cycle* **2013**, *12*, 674–683. [[CrossRef](#)]
28. Šileikytė, J.; Forte, M. The Mitochondrial Permeability Transition in Mitochondrial Disorders. *Oxidative Med. Cell. Longev.* **2019**, *2019*, 3403075. [[CrossRef](#)]
29. Bonora, M.; Wieckowski, M.R.; Chinopoulos, C.; Kepp, O.; Kroemer, G.; Galluzzi, L.; Pinton, P. Molecular mechanisms of cell death: Central implication of ATP synthase in mitochondrial permeability transition. *Oncogene* **2015**, *34*, 1475–1486. [[CrossRef](#)] [[PubMed](#)]
30. Rizzuto, R.; Marchi, S.; Bonora, M.; Aguiari, P.; Bononi, A.; Stefani, D.D.; Giorgi, C.; Leo, S.; Rimessi, A.; Siviero, R.; et al. Ca²⁺ transfer from the ER to mitochondria: When, how and why. *Biochim. Biophys. Acta* **2009**, *1787*, 1342–1351. [[CrossRef](#)] [[PubMed](#)]
31. Berridge, M.J.; Bootman, M.D.; Roderick, H.L. Calcium signalling: Dynamics, homeostasis and remodelling. *Nat. Rev. Mol. Cell Biol.* **2003**, *4*, 517–529. [[CrossRef](#)]
32. Giorgi, C.; Missiroli, S.; Patergnani, S.; Duszynski, J.; Wieckowski, M.R.; Pinton, P. Mitochondria-associated membranes: Composition, molecular mechanisms, and physiopathological implications. *Antioxid. Redox Signal.* **2015**, *22*, 995–1019. [[CrossRef](#)]
33. Pinton, P.; Ferrari, D.; Rapizzi, E.; Virgilio, F.D.; Pozzan, T.; Rizzuto, R. The Ca²⁺ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: Significance for the molecular mechanism of Bcl-2 action. *EMBO* **2001**, *20*, 2690–2701. [[CrossRef](#)]
34. Pinton, P.; Ferrari, D.; Magalhaes, P.; Schulze-Osthoff, K.; Virgilio, F.D.; Pozzan, T.; Rizzuto, R. Reduced loading of intracellular Ca²⁺ stores and downregulation of capacitative Ca²⁺ influx in Bcl-2-overexpressing cells. *J. Cell Biol.* **2000**, *148*, 857–862. [[CrossRef](#)]
35. Foyouzi-Youssefi, R.; Arnaudeau, S.; Borner, C.; Kelley, W.L.; Tschopp, J.; Lew, D.P.; Demaurex, N.; Krause, K.H. Bcl-2 decreases the free Ca²⁺ concentration within the endoplasmic reticulum. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 5723–5728. [[CrossRef](#)] [[PubMed](#)]
36. Akl, H.; Vervloessem, T.; Kiviluoto, S.; Bittremieux, M.; Parys, J.B.; Smedt, H.D.; Bultynck, G. A dual role for the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus endoplasmic reticulum. *Biochim. Biophys. Acta* **2014**, *1843*, 2240–2252. [[CrossRef](#)] [[PubMed](#)]

37. Akl, H.; Bultynck, G. Altered Ca^{2+} signaling in cancer cells: Proto-oncogenes and tumor suppressors targeting IP₃ receptors. *Biochim. Biophys. Acta* **2013**, *1835*, 180–193. [CrossRef]
38. Marchi, S.; Marinello, M.; Bononi, A.; Bonora, M.; Giorgi, C.; Rimessi, A.; Pinton, P. Selective modulation of subtype III IP₃R by Akt regulates ER Ca^{2+} release and apoptosis. *Cell Death Dis.* **2012**, *3*, e304. [CrossRef]
39. Giorgi, C.; Ito, K.; Lin, H.K.; Santangelo, C.; Wieckowski, M.R.; Lebedzinska, M.; Bononi, A.; Bonora, M.; Duszynski, J.; Bernardi, R.; et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. *Science* **2019**, *330*, 1247–1251. [CrossRef]
40. Stewart, T.A.; Yapa, K.T.; Monteith, G.R. Altered calcium signaling in cancer cells. *Biochim. Biophys. Acta* **2015**, *1848*, 2502–2511. [CrossRef] [PubMed]
41. Bononi, A.; Bonora, M.; Marchi, S.; Missiroli, S.; Poletti, F.; Giorgi, C.; Pandolfi, P.P.; Pinton, P. Identification of PTEN at the ER and MAMs and its regulation of Ca^{2+} signaling and apoptosis in a protein phosphatase-dependent manner. *Cell Death Differ.* **2013**, *20*, 1631–1643. [CrossRef] [PubMed]
42. Giorgi, C.; Bonora, M.; Sorrentino, G.; Missiroli, S.; Poletti, F.; Suski, J.M.; Galindo Ramirez, F.; Rizzuto, R.; Di Virgilio, F.; Zito, E.; et al. p53 at the endoplasmic reticulum regulates apoptosis in a Ca^{2+} -dependent manner. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 1779–1784. [CrossRef]
43. Giorgi, C.; Bonora, M.; Missiroli, S.; Poletti, F.; Ramirez, F.G.; Morciano, G.; Morganti, C.; Pandolfi, P.P.; Mammano, F.; Pinton, P. Intravital imaging reveals p53-dependent cancer cell death induced by phototherapy via calcium signaling. *Oncotarget* **2015**, *6*, 1435–1445. [CrossRef]
44. Rimessi, A.; Marchi, S.; Patergnani, S.; Pinton, P. H-Ras-driven tumoral maintenance is sustained through caveolin-1-dependent alterations in calcium signaling. *Oncogene* **2014**, *33*, 2329–2340. [CrossRef]
45. Lucia, U.; Grisolia, G. Constructal law and ion transfer in normal and cancer cells. *Proc. Rom. Acad. Ser. A* **2018**, *19*, 213–218.
46. Lucia, U.; Grisolia, G. Non-Equilibrium Thermodynamic Approach to Ca^{2+} -Fluxes in Cancer. *Appl. Sci.* **2020**, *10*, 6737. [CrossRef]
47. Lucia, U.; Deisboeck, T.S. The importance of ion fluxes for cancer proliferation and metastasis: A thermodynamic analysis. *J. Theor. Biol.* **2018**, *445*, 1–8. [CrossRef] [PubMed]
48. Leo, M.; Argalski, S.; Schifers, M.; Hagenacker, T. Modulation of Voltage-Gated Sodium Channels by Activation of Tumor Necrosis Factor Receptor-1 and Receptor-2 in Small DRG Neurons of Rats. *Mediat. Inflamm.* **2015**, *2015*, 24942. [CrossRef] [PubMed]
49. Foster, K.R. Mechanisms of Interaction of Extremely Low Frequency Electric Fields and Biological Systems. *Radiat. Prot. Dosim.* **2003**, *106*, 301–310. [CrossRef]
50. Lucia, U. Statistical approach of the irreversible entropy variation. *Physica A* **2008**, *387*, 3454–3460. [CrossRef]
51. Lucia, U.; Grisolia, G. Constructal law analysis of ion transfer in living cells: Normal and cancer behaviour. In *Constructal Law & Second Law Conference, CLC2017*; Morega, A.M., Lorente, S., Eds.; The Publishing House of the Romanian Academy: Bucharest, Romania, 2017; pp. 348–369.
52. Atkins, P.; Paula, J.D. *Physical Chemistry for Life Sciences*; Oxford University Press: New York, NY, USA, 2006.
53. Ashrafuzzaman, M.; Tuszyński, J. *Membrane Biophysics*; Springer: Berlin, Germany, 2013.
54. Feynman, R.P.; Leighton, R.B.; Sands, M. *The Feynman Lectures on Physics, Volume II*; Addison-Wesley Publishing Company: Boston, MA, USA, 1963.
55. Lucia, U. Thermodynamic approach to nano-properties of cell membrane. *Physica A* **2014**, *407*, 185–191. [CrossRef]
56. Lucia, U.; Grisolia, G.; Ponzetto, A.; Silvagno, F. An engineering thermodynamic approach to select the electromagnetic wave effective on cell growth. *J. Theor. Biol.* **2017**, *429*, 181–189. [CrossRef]
57. Bejan, A. *Heat Transfer*; Wiley: New York, NY, USA, 2011.
58. Bejan, A. *Shape and Structure, from Engineering to Nature*; Cambridge University Press: Cambridge, UK, 2000.
59. Lucia, U.; Grisolia, G.; Ponzetto, A.; Deisboeck, T.S. Thermodynamic considerations on the role of heat and mass transfer in biochemical causes of carcinogenesis. *Physica A* **2018**, *490*, 1164–1170. [CrossRef]
60. Lucia, U.; Bergandi, L.; Grisolia, G.; Fino, D.; Mareschi, K.; Marini, E.; Banche Niclot, A.G.S.; Tirtei, E.; Asaftei, S.D.; Fagioli, F.; et al. The exposure to extremely low frequency electromagnetic-fields inhibits the growth and potentiates the sensitivity to chemotherapy of bidimensional and tridimensional human osteosarcoma models. *Biomed. Pharmacother.* **2024**, *177*, 117162. [CrossRef]
61. Bergandi, L.; Lucia, U.; Grisolia, G.; Salaroglio, I.C.; Gesmundo, I.; Granata, R.; Borchiellini, R.; Ponzetto, A.; Silvagno, F. Thermomagnetic Resonance Effect of the Extremely Low Frequency Electromagnetic Field on Three-Dimensional Cancer Models. *Int. J. Mol. Sci.* **2022**, *23*, 7955. [CrossRef] [PubMed]
62. Bergandi, L.; Lucia, U.; Grisolia, G.; Granata, R.; Gesmundo, I.; Ponzetto, A.; Paolucci, E.; Borchiellini, R.; Ghigo, E.; Silvagno, F. The extremely low frequency electromagnetic stimulation selective for cancer cells elicits growth arrest through a metabolic shift. *BBA Mol. Cell Res.* **2019**, *1866*, 1389–1397. [CrossRef] [PubMed]
63. Tesla, N. High Frequency Oscillators for Electro-Therapeutic and Other Purposes. *Electr. Eng.* **1898**, *XXVI*, 477–481. [CrossRef]
64. Valone, T.F. Bioelectromagnetic Healing, its History and a Rationale for its Use. In *Proceedings of the Whole Person Healing Conference*; Iuniverse Inc.: Bethesda, MD, USA, 2003. Available online: <https://www.pecfund.com/ioe/pdf/BEMsHealingRationale.PDF> (accessed on 19 July 2024)
65. Manning, C.A.; Vanrenen, L.J. *Bioenergetic Medicines East and West*; North Atlantic Books: Berkeley, CA, USA, 1988.
66. Douglass, W.C. *Into the Light—The Exciting Story of the Life-Saving Breakthrough Therapy of the Age*; Second Opinion Pub.: Atlanta, GA, USA, 1996.

67. Lakhovsky, G. Curing Cancer with Ultra Radio Frequencies. *Radio News* **1925**, 1282–1283.
68. Liboff, A.R. Electric-field Ion Cyclotron Resonance. *BioElectroMagnetics* **1998**, *18*, 85–87. [[CrossRef](#)]
69. Arango-Restrepo, A.; Rubi, J.M. Predicting cancer stages from tissue energy dissipation. *Sci. Rep.* **2023**, *13*, 15894. [[CrossRef](#)] [[PubMed](#)]
70. Lucia, U.; Sciubba, E. From Lotka to the entropy generation approach. *Physica A* **2013**, *392*, 3634–3639. [[CrossRef](#)]
71. Lucia, U.; Ponzetto, A.; Deisboeck, T.S. A thermodynamic approach to the ‘mitosis/apoptosis’ ratio in cancer. *Physica A* **2015**, *436*, 246–255. [[CrossRef](#)]
72. Lucia, U. Thermodynamics and cancer stationary states. *Physica A* **2013**, *392*, 3648–3653. [[CrossRef](#)]
73. Cone, C.D. Electroosmotic interactions accompanying mitosis initiation in sarcoma cells in vitro. *Trans. N. Y. Acad. Sci.* **1969**, *31*, 404–427. [[CrossRef](#)]
74. Cone, C.D. Variation of the transmembrane potential level as a basic mechanism of mitosis control. *Oncology* **1970**, *24*, 438–470. [[CrossRef](#)] [[PubMed](#)]
75. Cone, C.D. Unified theory on the basic mechanism of normal mitotic control and oncogenesis. *J. Theor. Biol.* **1971**, *30*, 151–181. [[CrossRef](#)] [[PubMed](#)]
76. Markov, M.S. Expanding use of pulsed electromagnetic field therapies. *Electromagn. Biol. Med.* **2007**, *26*, 257–274. [[CrossRef](#)]
77. Salvatore, J.R.; Harrington, J.; Kummet, T. Phase I clinical study of a static magnetic field combined with anti-neoplastic chemotherapy in the treatment of human malignancy: Initial safety and toxicity data. *Bioelectromagnetics* **2003**, *24*, 524–527. [[CrossRef](#)]
78. Salzberg, M.H.; Kirson, E.H.; Palti, Y.H.; Rochlitz, C.H. A pilot study with very low intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumours. *Onkologie* **2008**, *31*, 362–365. [[CrossRef](#)]
79. Jimenez-Garcia, M.N.; Arellanes-Robledo, J.; Aparicio Bautista, D.I.; Rodriguez-Segura, M.A.; Villa-Trevino, S.; Godina-Nava, J.J. Anti-proliferative effect of an extremely low frequency electromagnetic field on preneoplastic lesions formation in the rat liver. *BMC Cancer* **2010**, *24*, 159. [[CrossRef](#)] [[PubMed](#)]
80. Costa, F.P.; de Oliveira, A.C.; Meirelles, R.; Machado, M.C.; Zanesco, T.; Surjan, R.; Chammas, M.C.; de Souza Rocha, M.; Morgan, D.; Cantor, A.; et al. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. *Br. J. Cancer* **2011**, *105*, 640–648. [[CrossRef](#)]
81. Barbault, A.; Costa, F.P.; Bottger, B.; Munden, R.F.; Bomholt, F.; Kuster, N.; Pasche, B. Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumour-specific frequencies and assessment of a novel therapeutic approach. *J. Exp. Clin. Cancer Res.* **2009**, *28*, 51. [[CrossRef](#)]
82. Ronchetto, F.; Barone, D.; Cintonino, M.; Berardelli, M.; Lissolo, S.; Orlassino, R.; Ossola, P.; Tofani, S. Extremely low frequency-modulated static magnetic fields to treat cancer: A pilot study on patients with advanced neoplasm to assess safety and acute toxicity. *Bioelectromagnetics* **2004**, *25*, 563–571. [[CrossRef](#)]
83. Strelczyk, D.; Eichhorn, M.E.; Luedemann, S.; Brix, G.; Dellian, M.; Berghaus, A.; Strieth, S. Static magnetic fields impair angiogenesis and growth of solid tumours in vivo. *Cancer Biol. Ther.* **2009**, *8*, 756–762. [[CrossRef](#)]
84. Strieth, S.; Strelczyk, D.; Eichhorn, M.E.; Dellian, M.; Luedemann, S.; Griebel, J.; Bellemann, M.; Berghaus, A.; Brix, G. Static magnetic fields induce blood flow decrease and platelet adherence in tumour microvessels. *Cancer Biol. Ther.* **2008**, *7*, 814–819. [[CrossRef](#)] [[PubMed](#)]
85. Williams, C.D.; Markov, M.S.; Hardman, W.E.; Cameron, I.L. Therapeutic electromagnetic field effects on angiogenesis and tumour growth. *Anticancer Res.* **2001**, *21*, 3887–3892. [[CrossRef](#)]
86. Chen, W.F.; Qi, H.; Sun, R.G.; Liu, Y.; Zhang, K.; Liu, J.Q. Static magnetic fields enhanced the potency of cisplatin on K562 cells. *Cancer Biother. Radiopharm.* **2010**, *25*, 401–408. [[CrossRef](#)] [[PubMed](#)]
87. Gray, J.R.; Frith, C.H.; Parker, J.D. In vivo enhancement of chemotherapy with static electric or magnetic fields. *Bioelectromagnetics* **2000**, *21*, 575–583. [[CrossRef](#)]
88. Janigro, D.; Perju, C.; Fazio, V.; Hallene, K.; Dini, G.; Agarwal, M.K.; Cucullo, L. Alternating current electrical stimulation enhanced chemotherapy: A novel strategy to bypass multidrug resistance in tumour cells. *BMC Cancer* **2006**, *17*, 6–72. [[CrossRef](#)]
89. Hirata, M.; Kuzuzaki, K.; Takeshita, H.; Hashiguchi, S.; Hirasawa, Y.; Ashihara, T. Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. *Anticancer Res.* **2001**, *21*, 317–320.
90. Rossi, E.; Corsetti, M.T.; Sukkar, S.; Poggi, C. Extremely Low Frequency Electromagnetic Fields Prevents Chemotherapy Induced Myelotoxicity. *BMC Cancer* **2007**, *26*, 277–281. [[CrossRef](#)]
91. Sun, C.T.; Yu, H.M.; Wang, X.W.; Han, J.Q. A pilot study of extremely low frequency magnetic fields in advanced non-small cell lung cancer. Effects on survival and palliation of general symptoms. *Oncol. Lett.* **2012**, *4*, 1130–1134. [[CrossRef](#)] [[PubMed](#)]
92. Ross, C.L.; Teli, T.; Harrison, B.S. Electromagnetic Field Devices and Their Effects on Nociception and Peripheral Inflammatory Pain Mechanisms. *Altern. Ther. Health Med.* **2016**, *22*, 52–64.
93. Patruno, A.; Amerio, P.; Pesce, M.; Vianale, G.; Di Luzio, S.; Tulli, A.; Franceschelli, S.; Grilli, A.; Muraro, R.; Reale, M. Extremely low frequency electromagnetic fields modulate expression of inducible nitric oxide synthase, endothelial nitric oxide synthase and cyclooxygenase-2 in the human keratinocyte cell line HaCaT: Potential therapeutic effects in wound healing. *Br. J. Dermatol.* **2010**, *162*, 258–266. [[CrossRef](#)]
94. Hiemer, B.; Ziebart, J.; Jonitz-Heincke, A.; Grunert, P.C.; Su, Y.; Hansmann, D.; Bader, R. Magnetically induced electrostimulation of human osteoblasts results in enhanced cell viability and osteogenic differentiation. *Int. J. Mol. Med.* **2016**, *38*, 57–64. [[CrossRef](#)]

95. Atalay, Y.; Gunes, N.; Guner, M.D.; Akpolat, V.; Celik, M.S.; Guner, R. Pentoxifylline and electromagnetic field improved bone fracture healing in rats. *Drug Des. Dev. Ther.* **2016**, *9*, 5195–5201. [[CrossRef](#)] [[PubMed](#)]
96. Pilla, A.A. Nonthermal electromagnetic fields: From first messenger to therapeutic applications. *Electromagn. Biol. Med.* **2013**, *32*, 123–136. [[CrossRef](#)]
97. Ross, C.L.; Syed, I.; Smith, T.L.; Harrison, B.S. The regenerative effects of electromagnetic field on spinal cord injury. *Electromagn. Biol. Med.* **2016**, *36*, 74–87. [[CrossRef](#)]
98. Vianale, G.; Reale, M.; Amerio, P.; Stefanachi, M.; Di Luzio, S.; Muraro, R. Extremely low frequency electromagnetic field enhances human keratinocyte cell growth and decreases proinflammatory chemokine production. *Br. J. Dermatol.* **2008**, *158*, 1189–1196. [[CrossRef](#)]
99. Ganesan, K.; Gengadharan, A.C.; Balachandran, C.; Manohar, B.M.; Puvanakrishnan, R. Low frequency pulsed electromagnetic field—A viable alternative for arthritis. *Indian J. Exp. Biol.* **2009**, *47*, 939–948. [[PubMed](#)]
100. Lee, P.B.; Kim, Y.C.; Lim, Y.J.; Lee, C.J.; Choi, S.S.; Park, S.H.; Lee, J.G.; Lee, S.C. Efficacy of pulsed electromagnetic therapy for chronic lower back pain: A randomized, double-blind, placebo-controlled study. *J. Int. Med. Res.* **2006**, *34*, 160–167. [[CrossRef](#)] [[PubMed](#)]
101. Weintraub, M.; Cole, S. A randomized controlled trial of the effects of a combination of static and dynamic fields on carpal tunnel syndrome. *J. Exp. Clin. Cancer Res.* **2008**, *9*, 493–504. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.